Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary Revance Releases First Quarter 2018 Results
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31, 2018 .
View HTML
Toggle Summary Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics , Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn McDowell as Senior
View HTML
Toggle Summary Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA Phase 3
View HTML
Toggle Summary Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018
-Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release
View HTML
Toggle Summary Revance Investor Day Highlights New Neuroscience Indications in Development
- Lead product for treatment of glabellar lines on track to report SAKURA Phase 3 open-label safety results in second half of 2018 - - Initiating Phase 3 pivotal trial for cervical dystonia in current quarter - - Company to add RT002 clinical programs in adult upper limb spasticity and chronic
View HTML
Toggle Summary Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic
View HTML
Toggle Summary Revance to Host Investor Day on April 19, 2018
- Webcast to begin at 12:00pm ET - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will host a live webcast of its
View HTML
Toggle Summary Revance to Participate in the Needham Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York,
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in two upcoming investor conferences.
View HTML
Toggle Summary Revance Releases Fourth Quarter and Full Year 2017 Results
- Announces collaboration and license agreement with Mylan for proposed biosimilar to BOTOX ® - -Cash and investments of approximately $283 million as of December 31, 2017 - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools